Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan - PubMed (original) (raw)
Review
. 1997 Sep:46 Suppl 2:S98-100.
doi: 10.2337/diab.46.2.s98.
Affiliations
- PMID: 9285508
- DOI: 10.2337/diab.46.2.s98
Review
Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan
T Jensen. Diabetes. 1997 Sep.
Abstract
Insulin-dependent diabetic patients with increased urinary albumin excretion are characterized by elevated blood pressure and declining kidney function. In addition, such patients have a high risk of atherosclerotic vascular disease, proliferative retinopathy, and cardiomyopathy, suggesting that albuminuria is a marker of widespread vascular dysfunction. Increased transport of macromolecules across the vascular wall, elevated plasma levels of von Willebrand factor, and impaired fibrinolytic capacity have been demonstrated in albuminuric patients. The cause of this vascular vulnerability in susceptible patients is unknown, but increasing evidence has suggested that loss of the proteoglycan heparan sulfate in the vasculature may explain the widespread nature of the disease. Heparan sulfate is important for the glomerular endothelial cell and basement membrane charge densities, the anticoagulant properties of the vessel wall, and the growth regulation of intimal smooth muscle cells. Recent studies have shown that heparin increases the biosynthesis of heparan sulfate in endothelial cell cultures and prevents the characteristic glomerular basement membrane thickening when given to diabetic rats. Moreover, heparin has been shown to reduce albuminuria in patients with incipient diabetic nephropathy. Although increasing evidence supports the hypothesis that loss of heparan sulfate may play a pathophysiological role in the development of diabetic vascular complications, there are still many unresolved problems. What are the mechanisms of action of glycosaminoglycans at the molecular biology level, and how can we select compounds without anticoagulant activity suitable for long-term use in the prevention and treatment of late diabetic complications?
Similar articles
- Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats.
Reddi AS, Ramamurthi R, Miller M, Dhuper S, Lasker N. Reddi AS, et al. Biochem Med Metab Biol. 1991 Feb;45(1):119-31. doi: 10.1016/0885-4505(91)90014-c. Biochem Med Metab Biol. 1991. PMID: 2015105 - Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin.
Lewis EJ, Xu X. Lewis EJ, et al. Diabetes Care. 2008 Feb;31 Suppl 2:S202-7. doi: 10.2337/dc08-s251. Diabetes Care. 2008. PMID: 18227486 Review. - Release of glomerular heparan-35SO4 proteoglycan by heparin from glomeruli of streptozocin-induced diabetic rats.
Klein DJ, Oegema TR Jr, Brown DM. Klein DJ, et al. Diabetes. 1989 Jan;38(1):130-9. doi: 10.2337/diab.38.1.130. Diabetes. 1989. PMID: 2521210
Cited by
- Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria.
Yongwatana K, Supasyndh O, Satirapoj B. Yongwatana K, et al. J Diabetes Res. 2020 Aug 8;2020:2984680. doi: 10.1155/2020/2984680. eCollection 2020. J Diabetes Res. 2020. PMID: 32851094 Free PMC article. - Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans.
Cicero AF, Ertek S. Cicero AF, et al. Arch Med Sci. 2010 Aug 30;6(4):469-77. doi: 10.5114/aoms.2010.14456. Epub 2010 Sep 7. Arch Med Sci. 2010. PMID: 22371788 Free PMC article. - Changes in cardiac heparan sulfate proteoglycan expression and streptozotocin-induced diastolic dysfunction in rats.
Strunz CM, Matsuda M, Salemi VM, Nogueira A, Mansur AP, Cestari IN, Marquezini MV. Strunz CM, et al. Cardiovasc Diabetol. 2011 Apr 25;10:35. doi: 10.1186/1475-2840-10-35. Cardiovasc Diabetol. 2011. PMID: 21518435 Free PMC article. - Advanced glycation of the Arg-Gly-Asp (RGD) tripeptide motif modulates retinal microvascular endothelial cell dysfunction.
McDonald DM, Coleman G, Bhatwadekar A, Gardiner TA, Stitt AW. McDonald DM, et al. Mol Vis. 2009 Aug 5;15:1509-20. Mol Vis. 2009. PMID: 19668595 Free PMC article. - Serum xylosyltransferase activity in diabetic patients as a possible marker of reduced proteoglycan biosynthesis.
Götting C, Kuhn J, Kleesiek K. Götting C, et al. Diabetes Care. 2008 Oct;31(10):2018-9. doi: 10.2337/dc08-0909. Epub 2008 Jul 23. Diabetes Care. 2008. PMID: 18650370 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical